Unknown

Dataset Information

0

Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.


ABSTRACT: Death Receptor 5 (DR5) is a pro-apoptotic cell-surface receptor that is a potential therapeutic target in cancer. Despite the potency of DR5-targeting agents in preclinical models, the translation of these effects into the clinic remains disappointing. Herein, we report an alternative approach to exploiting DR5 tumor expression using antibody-targeted, chemotherapy-loaded nanoparticles. We describe the development of an optimized polymer-based nanotherapeutic incorporating both a functionalized polyethylene glycol (PEG) layer and targeting antibodies to limit premature phagocytic clearance whilst enabling targeting of DR5-expressing tumor cells. Using the HCT116 colorectal cancer model, we show that following binding to DR5, the nanoparticles activate caspase 8, enhancing the anti-tumor activity of the camptothecin payload both in vitro and in vivo. Importantly, the combination of nanoparticle-induced DR5 clustering with camptothecin delivery overcomes resistance to DR5-induced apoptosis caused by loss of BAX or overexpression of anti-apoptotic FLIP. This novel approach may improve the clinical activity of DR5-targeted therapeutics while increasing tumor-specific delivery of systemically toxic chemotherapeutics.

SUBMITTER: Schmid D 

PROVIDER: S-EPMC4429693 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.

Schmid Daniela D   Fay Francois F   Small Donna M DM   Jaworski Jakub J   Riley Joel S JS   Tegazzini Diana D   Fenning Cathy C   Jones David S DS   Johnston Patrick G PG   Longley Daniel B DB   Scott Christopher J CJ  

Molecular therapy : the journal of the American Society of Gene Therapy 20140723 12


Death Receptor 5 (DR5) is a pro-apoptotic cell-surface receptor that is a potential therapeutic target in cancer. Despite the potency of DR5-targeting agents in preclinical models, the translation of these effects into the clinic remains disappointing. Herein, we report an alternative approach to exploiting DR5 tumor expression using antibody-targeted, chemotherapy-loaded nanoparticles. We describe the development of an optimized polymer-based nanotherapeutic incorporating both a functionalized  ...[more]

Similar Datasets

| S-EPMC6071817 | biostudies-literature
| S-EPMC3846837 | biostudies-literature
| S-EPMC5620143 | biostudies-literature
| S-EPMC2752169 | biostudies-literature
| S-EPMC3705644 | biostudies-literature
| S-EPMC3112300 | biostudies-literature
| S-EPMC4204797 | biostudies-other
| S-EPMC5460989 | biostudies-literature
| S-EPMC8182643 | biostudies-literature
| S-EPMC8096163 | biostudies-literature